3 ARTICLES
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
01 Aug 2024
India’s largest pharma company has caught investors’ fancy and a lot of it is due to founder Dilip Shanghvi’s need to take a different path.
05 Jan 2023
A slap on the wrist from the regulator hasn’t really helped restore investors’ faith in a company dogged by multiple governance and ethical issues.
09 Mar 2021